WNT signalling pathways as therapeutic targets in cancer

Nature Reviews Cancer

Volumn 13, Issue 1, 2013, Pages 11-26

  Anastas, Jamie N ^a,b,c   Moon, Randall T ^a,c  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; DICKKOPF 1 PROTEIN; FRIZZLED PROTEIN; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; WNT PROTEIN; WNT7A PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; BREAST CANCER; CANCER PATIENT; CELL DEATH; CELL DIFFERENTIATION; COLORECTAL CANCER; CORONARY ARTERY DISEASE; CRYSTAL STRUCTURE; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGUS CARCINOMA; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG CANCER; MEDULLOBLASTOMA; MELANOMA; MOLECULAR INTERACTION; NEOPLASM; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SARCOMA; SENESCENCE; SIGNAL TRANSDUCTION; STOMACH CANCER; WNT SIGNALING PATHWAY;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MICE; NEOPLASMS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 84871846692     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3419     Document Type: Review

References (200)

1. Papkoff, J., Brown, A. M. & Varmus, H. E. The int-1 proto-oncogene products are glycoproteins that appear to enter the secretory pathway. Mol. Cell. Biol. 7, 3978-3984 (1987).
2. Nusse, R. & Varmus, H. E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31, 99-109 (1982).
3. Nusse, R., Van Ooyen, A., Cox, D., Fung, Y. K. & Varmus, H. Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature 307, 131-136 (1984).
4. Tsukamoto, A. S., Grosschedl, R., Guzman, R. C., Parslow, T. & Varmus, H. E. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 55, 619-625 (1988).
5. Papkoff, J., Rubinfeld, B., Schryver, B. & Polakis, P. Wnt-1 regulates free pools of catenins and stabilizes APC-catenin complexes. Mol. Cell. Biol. 16, 2128-2134 (1996).
6. Korinek, V. et al. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC?/? colon carcinoma. Science 275, 1784-1787 (1997).
7. Morin, P. J. et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275, 1787-1790 (1997).
8. Kinzler, K. W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159-170 (1996).
9. Segditsas, S. & Tomlinson, I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 25, 7531-7537 (2006).
10. Angers, S. & Moon, R. T. Proximal events in Wnt signal transduction. Nature Rev. Mol. Cell. Biol. 10, 468-477 (2009).
11. Kohn, A. D. & Moon, R. T. Wnt and calcium signaling: β-catenin-independent pathways. Cell Calcium 38, 439-446 (2005).
12. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
13. Bass, A. J. et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nature Genet. 43, 964-968 (2011).
14. Laurent-Puig, P. & Zucman-Rossi, J. Genetics of hepatocellular tumors. Oncogene 25, 3778-3786 (2006).
15. Breuhahn, K., Longerich, T. & Schirmacher, P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 25, 3787-3800 (2006).
16. Zurawel, R. H., Chiappa, S. A., Allen, C. & Raffel, C. Sporadic medulloblastomas contain oncogenic β-catenin mutations. Cancer Res. 58, 896-899 (1998).
17. Palacios, J. & Gamallo, C. Mutations in the β-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res. 58, 1344-1347 (1998).
18. Salahshor, S. & Woodgett, J. R. The links between axin and carcinogenesis. J. Clin. Pathol. 58, 225-236 (2005).
19. Satoh, S. et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nature Genet. 24, 245-250 (2000).
20. Mani, A. et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 315, 1278-1282 (2007).
21. Robitaille, J. et al. Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy. Nature Genet. 32, 326-330 (2002).
22. De Ferrari, G. V. et al. Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc. Natl Acad. Sci. USA 104, 9434-9439 (2007).
23. Chim, C. S., Pang, R., Fung, T. K., Choi, C. L. & Liang, R. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 21, 2527-2536 (2007).
24. Klarmann, G. J., Decker, A. & Farrar, W. L. Epigenetic gene silencing in the Wnt pathway in breast cancer. Epigenetics 3, 59-63 (2008).
25. Aguilera, O. et al. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 25, 4116-4121 (2006).
26. Kansara, M. et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J. Clin. Invest. 119, 837-851 (2009).
27. Baldus, S. E. et al. MUC1 and nuclear β-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin. Cancer Res. 10, 2790-2796 (2004).
28. Lin, S. Y. et al. β-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc. Natl Acad. Sci. USA 97, 4262-4266 (2000).
29. Cheah, P. Y., Choo, P. H., Yao, J., Eu, K. W. & Seow-Choen, F. A survival-stratification model of human colorectal carcinomas with β-catenin and p27kip1. Cancer 95, 2479-2486 (2002).
30. Brabletz, T. et al. Nuclear overexpression of the oncoprotein β-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol. Res. Pract. 194, 701-704 (1998).
31. Cheng, H., Liang, H., Qin, Y. & Liu, Y. Nuclear β-catenin overexpression in metastatic sentinel lymph node is associated with synchronous liver metastasis in colorectal cancer. Diagn. Pathol. 6, 109 (2011).
32. Chung, G. G. et al. Tissue microarray analysis of β-catenin in colorectal cancer shows nuclear phospho-β-catenin is associated with a better prognosis. Clin. Cancer Res. 7, 4013-4020 (2001).
33. Bukholm, I. K., Nesland, J. M., Kresen, R., Jacobsen, U. & Brresen-Dale, A. L. E-cadherin and α-, β-, and γ-catenin protein expression in relation to metastasis in human breast carcinoma. J. Pathol. 185, 262-266 (1998).
34. Khramtsov, A. I. et al. Wnt/β-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am. J. Pathol. 176, 2911-2920 (2010).
35. Lσpez-Knowles, E. et al. Cytoplasmic localization of β-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol. Biomarkers Prev. 19, 301-309 (2010).
36. Fattet, S. et al. β-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J. Pathol. 218, 86-94 (2009).
37. Ellison, D. W. et al. β-catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J. Clin. Oncol. 23, 7951-7957 (2005).
38. Horvath, L. G. et al. Lower levels of nuclear β-catenin predict for a poorer prognosis in localized prostate cancer. Int. J. Cancer 113, 415-422 (2005).
39. Gamallo, C. et al. β-catenin expression pattern in stage I and II ovarian carcinomas: relationship with β-catenin gene mutations, clinicopathological features, and clinical outcome. Am. J. Pathol. 155, 527-536 (1999).
40. Chien, A. J. et al. Activated Wnt/β-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc. Natl Acad. Sci. USA 106, 1193-1198 (2009).
41. Bittner, M. et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536-540 (2000).
42. Weeraratna, A. T. et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1, 279-288 (2002).
43. Da Forno, P. D. et al. WNT5A expression increases during melanoma progression and correlates with outcome. Clin. Cancer Res. 14, 5825-5832 (2008).
44. Kurayoshi, M. et al. Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res. 66, 10439-10448 (2006).
45. Lejeune, S., Huguet, E. L., Hamby, A., Poulsom, R. & Harris, A. L. Wnt5a cloning, expression, and up-regulation in human primary breast cancers. Clin. Cancer Res. 1, 215-222 (1995).
46. Dejmek, J., Dejmek, A., Säfholm, A., Sjölander, A. & Andersson, T. Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res. 65, 9142-9146 (2005).
47. Wong, G. T., Gavin, B. J. & McMahon, A. P. Differential transformation of mammary epithelial cells by Wnt genes. Mol. Cell. Biol. 14, 6278-6286 (1994).
48. Shimizu, H. et al. Transformation by Wnt family proteins correlates with regulation of β-catenin. Cell Growth Differ. 8, 1349-1358 (1997).
49. Naylor, S. et al. Retroviral expression of Wnt-1 and Wnt-7b produces different effects in mouse mammary epithelium. J. Cell. Sci. 113, 2129-2138 (2000).
50. Qiang, Y.-W., Endo, Y., Rubin, J. S. & Rudikoff, S. Wnt signaling in B-cell neoplasia. Oncogene 22, 1536-1545 (2003).
51. Derksen, P. W. B. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc. Natl Acad. Sci. 101, 6122-6127 (2004).
52. Verras, M., Brown, J., Li, X., Nusse, R. & Sun, Z. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res. 64, 8860-8866 (2004).
53. Li, X. et al. Prostate tumor progression is mediated by a paracrine TGF-β/Wnt3a signaling axis. Oncogene 27, 7118-7130 (2008).
54. Pearson, H. B., Phesse, T. J. & Clarke, A. R. K-ras and Wnt Signaling synergize to accelerate prostate tumorigenesis in the mouse. Cancer Res. 69, 94-101 (2009).
55. Yu, X., Wang, Y., DeGraff, D. J., Wills, M. L. & Matusik, R. J. Wnt/β-Catenin activation promotes prostate tumor progression in a mouse model. Oncogene 30, 1868-1879 (2010).
56. Biechele, T. L. et al. Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci. Signal. 5, ra3 (2012).
57. Yoshioka, S. et al. WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway. Mol. Cancer Res. 10, 469-482 (2012).
58. Ochoa-Hernαndez, A. B. et al. Peripheral T-lymphocytes express WNT7A and its restoration in leukemia-derived lymphoblasts inhibits cell proliferation. BMC Cancer 12, 60 (2012).
59. Carmon, K. S. & Loose, D. S. Secreted frizzled-related protein 4 regulates two Wnt7a signaling pathways and inhibits proliferation in endometrial cancer cells. Mol. Cancer Res. 6, 1017-1028 (2008).
60. Guturi, K. K. N. et al. Mechanism of β-catenin-mediated transcriptional regulation of epidermal growth factor receptor expression in glycogen synthase kinase 3β-inactivated prostate cancer cells. J. Biol. Chem. 287, 18287-18296 (2012).
61. Bitler, B. G. et al. Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Res. 71, 6184-6194 (2011).
62. Kremenevskaja, N. et al. Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene 24, 2144-2154 (2005).
63. Liang, H. et al. Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell 4, 349-360 (2003).
64. Schwartz, A. L. et al. Phenylmethimazole decreases toll-like receptor 3 and noncanonical Wnt5a expression in pancreatic cancer and melanoma together with tumor cell growth and migration. Clin. Cancer Res. 15, 4114-4122 (2009).
65. Fukuda, T. et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc. Natl Acad. Sci. 105, 3047-3052 (2008).
66. Wu, A. et al. Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev. 17, 173-184 (2008).
67. King, T. D., Zhang, W., Suto, M. J. & Li, Y. Frizzled7 as an emerging target for cancer therapy. Cell. Signal. 24, 846-851 (2012).
68. Yang, L. et al. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene 30, 4437-4446 (2011).
69. Wei, W., Chua, M.-S., Grepper, S. & So, S. K. Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin. Mol. Cancer 10, 16 (2011).
70. Liu, J. et al. Enhancement of canonical Wnt/β-catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells. PLoS ONE 6, e27496 (2011).
71. Yamaguchi, T. et al. NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 21, 348-361 (2012).
72. Zhang, S. et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS ONE 7, e31127 (2012).
73. Gentile, A., Lazzari, L., Benvenuti, S., Trusolino, L. & Comoglio, P. M. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res. 71, 3132-3141 (2011).
74. Wright, T. M. et al. Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Oncogene 28, 2513-2523 (2009).
75. Edris, B. et al. ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J. Pathol. 227, 223-233 (2012).
76. Schlange, T., Matsuda, Y., Lienhard, S., Huber, A. & Hynes, N. E. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res. 9, R63 (2007).
77. Matsuda, Y., Schlange, T., Oakeley, E. J., Boulay, A. & Hynes, N. E. WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth. Breast Cancer Res. 11, R32 (2009).
78. DiMeo, T. A. et al. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 69, 5364-5373 (2009).
79. Horvath, L. G. et al. Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro. Clin. Cancer Res. 10, 615-625 (2004).
80. Zi, X. et al. Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res. 65, 9762-9770 (2005).
81. Joesting, M. S. et al. Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res. 65, 10423-10430 (2005).
82. Yee, D. S. et al. The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol. Cancer 9, 162 (2010).
83. Lambiv, W. L. et al. The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro Oncol. 13, 736-747 (2011).
84. Ramachandran, I. et al. Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo. Oncogene 31, 2725-2737 (2011).
85. Rubin, E. M. et al. Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol. Cancer Ther. 9, 731-741 (2010).
86. Nguyen, L. V., Vanner, R., Dirks, P. & Eaves, C. J. Cancer stem cells: an evolving concept. Nature Rev. Cancer 12, 133-143 (2012).
87. Yeung, J. et al.β-catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 18, 606-618 (2010).
88. Jamieson, C. H. M. et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351, 657-667 (2004).
89. Zhao, C. et al. Loss of β-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 12, 528-541 (2007).
90. Wang, Y. et al. The Wnt/β-catenin pathway is required for the development of leukemia stem cells in AML. Science 327, 1650-1653 (2010).
91. Barker, N. et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457, 608-611 (2009).
92. Van de Wetering, M. et al. The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111, 241-250 (2002).
93. Deka, J. et al. Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas. Cancer Res. 70, 6619-6628 (2010).
94. Steg, A. D. et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin. Cancer Res. 18, 869-881 (2011).
95. Li, Y. et al. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc. Natl Acad. Sci. USA 100, 15853-15858 (2003).
96. Shackleton, M. et al. Generation of a functional mammary gland from a single stem cell. Nature 439, 84-88 (2006).
97. Hallett, R. M. et al. Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer. PLoS ONE 7, e33976 (2012).
98. Zeng, Y. A. & Nusse, R. Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture. Cell Stem Cell 6, 568-577 (2010).
99. Scheel, C. et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145, 926-940 (2011).
100. Ye, X. et al. Downregulation of Wnt signaling is a trigger for formation of facultative heterochromatin and onset of cell senescence in primary human cells. Mol. Cell 27, 183-196 (2007).
101. Zhang, H. et al. Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/β-catenin pathway. Cancer Lett. 323, 106-113 (2012).
102. Noda, T. et al. Activation of Wnt/β-catenin signalling pathway induces chemoresistance to interferon-α/5-fluorouracil combination therapy for hepatocellular carcinoma. Br. J. Cancer 100, 1647-1658 (2009).
103. Flahaut, M. et al. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/β-catenin pathway. Oncogene 28, 2245-2256 (2009).
104. Bordonaro, M., Tewari, S., Cicco, C. E., Atamna, W. & Lazarova, D. L. A switch from canonical to noncanonical Wnt signaling mediates drug resistance in colon cancer cells. PLoS ONE 6, e27308 (2011).
105. Zhou, Z., Wang, J., Han, X., Zhou, J. & Linder, S. Up-regulation of human secreted frizzled homolog in apoptosis and its down-regulation in breast tumors. Int. J. Cancer 78, 95-99 (1998).
106. Shou, J. et al. Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. Oncogene 21, 878-889 (2002).
107. Mazieres, J. et al. Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis. Oncogene 24, 5396-5400 (2005).
108. Hirata, H. et al. Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int. J. Cancer 128, 1793-1803 (2011).
109. He, B. et al. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 6, 7-14 (2004).
110. MacKeigan, J. P., Murphy, L. O. & Blenis, J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nature Cell Biol. 7, 591-600 (2005).
111. Choudhury, A. et al. Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells. Br. J. Haematol. 151, 327-335 (2010).
112. Ueno, K. et al. Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells. Br. J. Cancer 101, 1374-1381 (2009).
113. Ueno, K. et al. Frizzled-7 as a potential therapeutic target in colorectal cancer. Neoplasia 10, 697-705 (2008).
114. Qiang, Y.-W. Wnts induce migration and invasion of myeloma plasma cells. Blood 106, 1786-1793 (2005).
115. Pukrop, T. Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. Proc. Natl Acad. Sci. 103, 5454-5459 (2006).
116. Ulivieri, A. et al. Frizzled-1 is down-regulated in follicular thyroid tumours and modulates growth and invasiveness. J. Pathol. 215, 87-96 (2008).
117. Fu, L. et al. Wnt2 secreted by tumour fibroblasts promotes tumour progression in oesophageal cancer by activation of the Wnt/β-catenin signalling pathway. Gut 60, 1635-1643 (2011).
118. Yook, J. I. et al. A Wnt-Axin2-GSK3β cascade regulates Snail1 activity in breast cancer cells. Nature Cell Biol. 8, 1398-1406 (2006).
119. Thiery, J. P. & Sleeman, J. P. Complex networks orchestrate epithelial-mesenchymal transitions. Nature Rev. Mol. Cell. Biol. 7, 131-142 (2006).
120. Etienne-Manneville, S., Manneville, J.-B., Nicholls, S., Ferenczi, M. A. & Hall, A. Cdc42 and Par6-PKCζ regulate the spatially localized association of Dlg1 and APC to control cell polarization. J. Cell Biol. 170, 895-901 (2005).
121. Schlessinger, K., McManus, E. J. & Hall, A. Cdc42 and noncanonical Wnt signal transduction pathways cooperate to promote cell polarity. J. Cell Biol. 178, 355-361 (2007).
122. Nguyen, D. X. et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138, 51-62 (2009).
123. Liu, L. et al. Activation of β-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. Clin. Cancer Res. 16, 2740-2750 (2010).
124. Arozarena, I. et al. In melanoma, β-catenin is a suppressor of invasion. Oncogene 30, 4531-4543 (2011).
125. Gallagher, S. J. et al. β-catenin inhibits melanocyte migration but induces melanoma metastasis. Oncogene 4 Jun 2012 (doi:10.1038/onc.2012.229).
126. Damsky, W. E. et al.β-catenin signaling controls metastasis in braf-activated pten-deficient melanomas. Cancer Cell 20, 741-754 (2011).
127. Malanchi, I. et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481, 85-89 (2012).
128. Syed Khaja, A. S. et al. Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcome. PLoS ONE 6, e26539 (2011).
129. Sδfholm, A. et al. A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells. J. Biol. Chem. 281, 2740-2749 (2006).
130. Witze, E. S., Litman, E. S., Argast, G. M., Moon, R. T. & Ahn, N. G. Wnt5a control of cell polarity and directional movement by polarized redistribution of adhesion receptors. Science 320, 365-369 (2008).
131. Dow, L. E. et al. The tumour-suppressor Scribble dictates cell polarity during directed epithelial migration: regulation of Rho GTPase recruitment to the leading edge. Oncogene 26, 2272-2282 (2007).
132. Anastas, J. N. et al. A protein complex of SCRIB, NOS1AP and VANGL1 regulates cell polarity and migration, and is associated with breast cancer progression. Oncogene 31, 3696-3708 (2012).
133. Lee, J. H. et al. KAI1 COOH-terminal interacting tetraspanin (KITENIN), a member of the tetraspanin family, interacts with KAI1, a tumor metastasis suppressor, and enhances metastasis of cancer. Cancer Res. 64, 4235-4243 (2004).
134. Na, H.-W., Shin, W.-S., Ludwig, A. & Lee, S.-T. The cytosolic domain of PTK7, generated from sequential cleavage by ADAM17 and γ-secretase, enhances cell proliferation and migration in colon cancer cells. J. Biol. Chem. 287, 25001-25009 (2012).
135. Golubkov, V. S. et al. The Wnt/planar cell polarity (PCP) protein tyrosine kinase-7 (PTK7) is a highly efficient proteolytic target of membrane type-1 matrix metalloproteinase (MT1-MMP): implications in cancer and embryogenesis. J. Biol. Chem. 285, 35740-35749 (2010).
136. Gao, B. et al. Wnt signaling gradients establish planar cell polarity by inducing Vangl2 phosphorylation through Ror2. Dev. Cell 20, 163-176 (2011).
137. O'Connell, M. P. et al. The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene 29, 34-44 (2010).
138. Enomoto, M. et al. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene 28, 3197-3208 (2009).
139. Reifenberger, J. et al. Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int. J. Cancer 100, 549-556 (2002).
140. Caldwell, C. M. & Kaplan, K. B. The role of APC in mitosis and in chromosome instability. Adv. Exp. Med. Biol. 656, 51-64 (2009).
141. Imbert, A., Eelkema, R., Jordan, S., Feiner, H. & Cowin, P. ΔN89β-catenin induces precocious development, differentiation, and neoplasia in mammary gland. J. Cell Biol. 153, 555-568 (2001).
142. Teissedre, B. et al. MMTV-Wnt1 and-ΔN89β-catenin induce canonical signaling in distinct progenitors and differentially activate Hedgehog signaling within mammary tumors. PLoS ONE 4, e4537 (2009).
143. Gounari, F. et al. Stabilization of β-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene 21, 4099-4107 (2002).
144. Wong, M. H., Rubinfeld, B. & Gordon, J. I. Effects of forced expression of an NH2-terminal truncated β-Catenin on mouse intestinal epithelial homeostasis. J. Cell Biol. 141, 765-777 (1998).
145. Damalas, A., Kahan, S., Shtutman, M., Ben-Ze'ev, A. & Oren, M. Deregulated β-catenin induces a p53-and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J. 20, 4912-4922 (2001).
146. Halberg, R. B. et al. Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers. Proc. Natl Acad. Sci. USA 97, 3461-3466 (2000).
147. Pacheco-Pinedo, E. C. et al. Wnt/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J. Clin. Invest. 121, 1935-1945 (2011).
148. Delmas, V. et al. β-Catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev. 21, 2923-2935 (2007).
149. Bulut, G. et al.β-catenin accelerates human papilloma virus type-16 mediated cervical carcinogenesis in transgenic mice. PLoS ONE 6, e27243 (2011).
150. Smith, M. L., Hawcroft, G. & Hull, M. A. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur. J. Cancer 36, 664-674 (2000).
151. Dihlmann, S., Siermann, A. & Von Knebel Doeberitz, M. The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate β-catenin/TCF-4 signaling. Oncogene 20, 645-653 (2001).
152. Tuynman, J. B. et al. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res. 68, 1213-1220 (2008).
153. Labayle, D. et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101, 635-639 (1991).
154. Giardiello, F. M. et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328, 1313-1316 (1993).
155. Phillips, R. K. S. et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50, 857-860 (2002).
156. Steinbach, G. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1946-1952 (2000).
157. Chen, B. et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nature Chem. Biol. 5, 100-107 (2009).
158. Thorne, C. A. et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. Nature Chem. Biol. 6, 829-836 (2010).
159. Huang, S.-M. A. et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614-620 (2009).
160. Gonsalves, F. C. et al. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc. Natl Acad. Sci. USA 108, 5954-5963 (2011).
161. Wang, W., Liu, H., Wang, S., Hao, X. & Li, L. A diterpenoid derivative 15-oxospiramilactone inhibits Wnt/β-catenin signaling and colon cancer cell tumorigenesis. Cell Res. 21, 730-740 (2011).
162. Lepourcelet, M. et al. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell 5, 91-102 (2004).
163. Tian, W. et al. Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction. Biochemistry 51, 724-731 (2012).
164. Shan, J., Shi, D.-L., Wang, J. & Zheng, J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry 44, 15495-15503 (2005).
165. Fujii, N. et al. An antagonist of dishevelled protein-protein interaction suppresses β-catenin-dependent tumor cell growth. Cancer Res. 67, 573-579 (2007).
166. Grandy, D. et al. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J. Biol. Chem. 284, 16256-16263 (2009).
167. Zhang, Y. et al. Inhibition of Wnt signaling by Dishevelled PDZ peptides. Nature Chem. Biol. 5, 217-219 (2009).
168. Nambotin, S. B. et al. Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. J. Hepatol. 54, 288-299 (2011).
169. Reya, T. et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423, 409-414 (2003).
170. Willert, K. et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 423, 448-452 (2003).
171. Chen, S. et al. Wnt-1 signaling inhibits apoptosis by activating β-catenin/T cell factor-mediated transcription. J. Cell Biol. 152, 87-96 (2001).
172. Mikami, I. et al. Efficacy of Wnt-1 monoclonal antibody in sarcoma cells. BMC Cancer 5, 53 (2005).
173. Pode-Shakked, N. et al. Resistance or sensitivity of Wilms' tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target. Oncogene 30, 1664-1680 (2011).
174. Ettenberg, S. A. et al. Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc. Natl Acad. Sci. USA 107, 15473-15478 (2010).
175. Hudecek, M. et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 116, 4532-4541 (2010).
176. Yang, J. et al. Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS ONE 6, e21018 (2011).
177. Lavergne, E. et al. Blocking Wnt signaling by SFRP-like molecules inhibits in vivo cell proliferation and tumor growth in cells carrying active β-catenin. Oncogene 30, 423-433 (2011).
178. Sδfholm, A. et al. The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin. Cancer Res. 14, 6556-6563 (2008).
179. DeAlmeida, V. I. et al. The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res. 67, 5371-5379 (2007).
180. Janda, C. Y., Waghray, D., Levin, A. M., Thomas, C. & Garcia, K. C. Structural basis of Wnt recognition by frizzled. Science 337, 59-64 (2012).
181. Ohigashi, T., Mizuno, R., Nakashima, J., Marumo, K. & Murai, M. Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate 62, 61-68 (2005).
182. Peng, C., Zhang, X., Yu, H., Wu, D. & Zheng, J. Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer. Int. J. Gynecol. Cancer 21, 280-288 (2011).
183. Zucman-Rossi, J. et al. Differential effects of inactivated Axin1 and activated β-catenin mutations in human hepatocellular carcinomas. Oncogene 26, 774-780 (2007).
184. Arce, L., Yokoyama, N. N. & Waterman, M. L. Diversity of LEF/TCF action in development and disease. Oncogene 25, 7492-7504 (2006).
185. Tang, W. et al. A genome-wide RNAi screen for Wnt/β-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. Proc. Natl Acad. Sci. USA 105, 9697-9702 (2008).
186. Truica, C. I., Byers, S. & Gelmann, E. P. β-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res. 60, 4709-4713 (2000).
187. Pαlmer, H. G. et al. Vitamin D3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of β-catenin signaling. J. Cell Biol. 154, 369-387 (2001).
188. Easwaran, V., Pishvaian, M., Salimuddin & Byers, S. Cross-regulation of β-catenin-LEF/TCF and retinoid signaling pathways. Curr. Biol. 9, 1415-1418 (1999).
189. Yang, F. et al. Linking β-catenin to androgen-signaling pathway. J. Biol. Chem. 277, 11336-11344 (2002).
190. Shah, S. et al. The molecular basis of vitamin D receptor and β-catenin crossregulation. Mol. Cell 21, 799-809 (2006).
191. Yang, J. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 14, 818-829 (2008).
192. Medrek, C., Landberg, G., Andersson, T. & Leandersson, K. Wnt-5a-CKIα signaling promotes β-catenin/E-cadherin complex formation and intercellular adhesion in human breast epithelial cells. J. Biol. Chem. 284, 10968-10979 (2009).
193. Qi, L. et al. Dickkopf-1 inhibits epithelial-mesenchymal transition of
194. Ren, D., Minami, Y. & Nishita, M. Critical role of Wnt5a-Ror2 signaling in motility and invasiveness of carcinoma cells following Snail-mediated epithelial-mesenchymal transition. Genes Cells 16, 304-315 (2011).
195. Djiane, A., Riou, J., Umbhauer, M., Boucaut, J. & Shi, D. Role of frizzled 7 in the regulation of convergent extension movements during gastrulation in Xenopus laevis. Development 127, 3091-3100 (2000).
196. Habas, R., Kato, Y. & He, X. Wnt/Frizzled activation of Rho regulates vertebrate gastrulation and requires a novel Formin homology protein Daam1. Cell 107, 843-854 (2001).
197. Habas, R., Dawid, I. B. & He, X. Coactivation of Rac and Rho by Wnt/Frizzled signaling is required for vertebrate gastrulation. Genes Dev. 17, 295-309 (2003).
198. Wansleeben, C. & Meijlink, F. The planar cell polarity pathway in vertebrate development. Dev. Dyn. 240, 616-626 (2011).
199. Lai, S.-L., Chien, A. J. & Moon, R. T. Wnt/Fz signaling and the cytoskeleton: potential roles in tumorigenesis. Cell Res. 19, 532-545 (2009).
200. Hansen, C. et al. Wnt-5a-induced phosphorylation of DARPP-32 inhibits breast cancer cell migration in a CREB-dependent manner. J. Biol. Chem. 284, 27533-27543 (2009).